Industry Insights

1. Innovating Bioequivalence: A Novel Approach To Developing Complex Generic Dosage Forms 4/16/2024

   Achieving bioequivalence for complex generics is an intricate task. This article describes an approach using in vitro–in vivo correlation, PBMK modeling, and more.

2. Pairing Robust Analytical Methods With Efficient Process Development 9/16/2024

   Analytical method development is a critical phase in development, and its successful implementation is essential for delivering high-quality products to market efficiently and effectively.

3. 10 Questions To Ask When Choosing A Cell Therapy CDMO 3/17/2026

   A strategic framework outlines ten critical questions to evaluate a manufacturing partner’s reliability, expertise, performance, and operational rigor to ensure successful, scalable cell‑therapy development.

4. COVID-19 Vaccine Manufacturing Challenges Spark Surge In Outsourcing Deals 10/19/2020

   As the pharma industry scrambles to develop one or more viable COVID-19 vaccines, the greatest hurdle to immunizing the world’s population is the manufacture of billions of doses in parallel. In response to this challenge, vaccine developers are signing an unprecedented number of outsourcing agreements with CMOs and other service providers.

5. The Hidden Engineering Behind Successful Upstream Bioprocessing 2/25/2026

   In upstream biopharmaceutical production, manufacturing is inseparable from biology, engineering, contamination control, and quality science.

6. Never Too Early To Plan For Automation 6/8/2020

   Early platform design selections can greatly affect your future automation flexibility and ability to show compliance throughout regulatory reviews.

7. Innovation That Is Evolving The CGT Landscape In 2025 7/28/2025

   Uncover how cell and gene therapy leaders are adapting to funding pressures, regulatory shifts, and global complexity by prioritizing scalability and strategic partnerships for long-term success.

8. Bracing For The Impact Of The Federal Workforce Reduction 6/9/2025

   The federal workforce reductions pose significant challenges for the life sciences industry, particularly for R&D, supply chain oversight, and industry workforce development.

9. Integrating Advocacy Into The Cell & Gene Therapy Supply Chain 6/2/2021

   Treating advocacy as an institutional priority provides tangible benefits for Aldevron’s team members, our clients, and, most importantly, the patients waiting for these potential breakthroughs.

10. 5 Reasons For Outsourcing Chromatography Resin Lifetime Studies 12/12/2025

    Outsourcing resin lifetime studies accelerates timelines, reduces costs, and minimizes risk. Gain expert support, free up resources, and optimize resin performance without tying up your team or equipment.